Skip to main content

Advertisement

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

Fig. 1

Targeting of CD22 by epratuzumab influences the secretion of the proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6, but not IL-10, by stimulated B cells. Peripheral blood B cells were purified from patients with systemic lupus erythematosus (SLE) (left) and healthy donors (HD) (right), pretreated with (gray squares) or without F(ab′)2 epratuzumab (open squares) and cultured with media alone (RPMI) or stimulated with anti–B cell receptor (anti-BCR) or anti-BCR + CpG. After 2 days of culture, the supernatants were harvested and tested for TNF-α, IL-6 and IL-10 protein production using a Bio-Plex Pro™ Human Th17 Cytokine Panel assay. Combined data from 13 patients with SLE and 9 HD are shown for TNF-α (a), IL-6 (b) and IL-10 (c) (Mann–Whitney U test; ns = not significant, *p < 0.05, **p < 0.01)

Back to article page